
    
      This is a multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose
      study in a total of 24 subjects (8 subjects per cohort) with MCI due to AD and mild AD. The
      study consists of three cohorts to evaluate the safety, tolerability and PK of BAN2401 at
      three dose levels (2.5, 5, and 10 mg/kg). Each cohort consists of Screening Period before
      randomization, Treatment Period from randomization to last dose, and Follow-up Period after
      last dose. Cohorts 1, 2, and 3 will receive 2.5 mg/kg, 5 mg/kg, and 10 mg/kg of BAN2401,
      respectively.
    
  